The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

Heart valve disease is a fairly common problem that happens when at least one of your four heart valves isn’t working ...

Sandra Lesenfants, senior vice president of Abbott’s Structural Heart business, shares an update on MitraClip, TriClip, and ...

Edwards Lifesciences (NYSE:EW) today announced data highlighting the superiority of its Evoque system compared to medical ...

CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment ...

A new study has found that new-onset left bundle-branch block after surgical aortic valve replacement is linked to increased ...

Israeli heart medical device company Innoventric today announced the completion of a $28.5 million Series B financing round.

Among those undergoing additional surgeries, 42% had a mitral/tricuspid valve intervention, 39% received an aortic valve ...

Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...

Jenscare Scientific Co., Ltd. ('Jenscare' or the 'Company') (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...

"Every patient has a unique tricuspid valve anatomy and disease etiology which can make device procedures complex. The DUO System is an important option in my treatment toolbox," said Dr. Yadav ...